1. Life Sciences

Cybersecurity and Data Privacy Concerns for Wearables – Duane Morris Life Sciences Law

Written by Posted on Less than 0 min read

Duane Morris Life Sciences Law

For Life Sciences innovators, challenges can be scientific, technical, business-related or legal, and Duane Morris’ lawyers share their insight into all these areas, from startup and financing, to licensing, IP, regulatory, litigation and more.

Member since

More from Duane Morris

  1. Life Sciences

FDA Releases Draft AI Guidance – A New Era for Biotech, Diagnostics and Regulatory Compliance – Duane Morris Life Sciences Law

The U.S. Food and Drug Administration’s recent release of two draft guidance documents on the use of artificial intelligence in drug development, biologics and medical devices has sparked both excitement and skepticism. As AI increasingly permeates these fields, the regulatory landscape is just beginning to take shape—and these proposed guidelines take […]
Written by
  1. Life Sciences

FDA’s New Rule Regulates Lab-Developed Tests Under FD&C Act – Duane Morris Life Sciences Law

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule that amends existing regulations to make explicit that in vitro diagnostic products and tests (IVDs), including laboratory developed tests (LDTs), are devices regulated under the Federal Food, Drug and Cosmetic Act (FD&C Act). LDTs have increased in volume, complexity and […]
Written by
  1. Life Sciences

Federal Court Grants EPA Request to Stay Litigation Challenging 2024 Ethylene Oxide Regulation Pending Agency’s Reconsideration

By Sharon L. Caffrey, Jeffrey S. Pollack and Coleen W. Hill In June 2024, industry and environmentalist parties filed a petition in the U.S. Court of Appeals for the District of Columbia Circuit for review of a national emission standards for hazardous air pollutants regulation applicable to commercial sterilization facilities, which was […]
Written by
  1. Life Sciences

Rick Ball and Coleen Hill to Speak at MassMEDIC Regulatory Roundup – Duane Morris Life Sciences Law

Duane Morris attorneys Rick Ball and Coleen Hill will be speakers at MassMEDIC’s Regulatory Roundup, to be held on November 15, 2023 from 8:00 a.m. to 4:15 p.m.  Rick and Coleen will present “When Things Go Wrong: Navigating Enforcement When the FDA, SEC, and DOJ Are All Involved.” For more information […]
Written by
  1. Life Sciences

Montana Set to Become a “Wild West” Hub for Experimental Medical Treatments and Therapies – Duane Morris Life Sciences Law

By Vicki G. Norton, Ph.D., and Brandon A. Chan Ph.D. The Federal Food, Drug and Cosmetic Act generally prohibits access to investigational drugs that have not yet been approved by the United States Food and Drug Administration. Patients that have been diagnosed with a life-threatening or seriously debilitating disease may request […]
Written by
  1. Life Sciences

What Companies Need to Know About Regulatory and IP Risks – Duane Morris Life Sciences Law

As the medtech AI market surges toward $615 billion by 2034, companies must navigate complex licensing, regulatory, and intellectual property challenges. Understanding these key issues is essential to unlocking the full potential of AI-driven healthcare innovation. The global market value for medical technology utilizing artificial intelligence (AI) is projected to reach […]
Written by
  1. Life Sciences

Federal Trade Commission Poised to File Suit Against Pharmacy Benefit Managers Based on Unlawful Medication Pricing – Duane Morris Life Sciences Law

On July 10, 2024, multiple media sources reported that the Federal Trade Commission intends to file suit against the nation’s three largest pharmacy benefit managers over​ allegations of improper pricing in connection with their negotiations with drug manufacturers that dramatically increased prices for consumers and lined the PBMs’ pockets with lucrative […]
Written by
  1. Life Sciences

Neighborhood Pharmacists Demand CMS Take Enforcement Motion Towards PBMs – Duane Morris Life Sciences Legislation

As information surfaced on February 27 that Congress is punting long-debated pharmacy profit supervisor reforms, the neighborhood pharmacy foyer demanded CMS instantly take enforcement motion in opposition to improper PBM practices that the foyer says may trigger almost a 3rd of impartial pharmacies to shutter this yr. […] Jonathan Swichar, associate […]
Written by
  1. Life Sciences

How They’ll Have an effect on Patent Prosecution Methods – Duane Morris Life Sciences Legislation

The USPTO is soliciting feedback relating to its proposed charge will increase for fiscal yr 2025. Written feedback have to be acquired on or earlier than June 3, 2024, to make sure consideration. Thus, it’s essential that each in-house attorneys and outdoors counsel assessment and contemplate how these adjustments, a few […]
Written by
  1. Life Sciences

The Changing Beauty Regulatory Landscape – Duane Morris Life Sciences Law

Duane Morris attorney Kelly Bonner was quoted in an article in WWD on June 25, 2024. “A big deadline in the beauty and personal care regulatory landscape is fast approaching, with much more to come — although some experts believe this still isn’t enough. Under the Modernization of Cosmetics Regulation Act, or MoCRA, passed […]
Written by
  1. Life Sciences

FDA’s Latest Draft Guidance on Medical Device PCCPs Incorporates FD&C Act Changes – Duane Morris Life Sciences Law

The U.S. Food and Drug Administration (FDA) recently issued draft Guidance informing medical device manufacturers how to structure a predetermined change control plan (PCCP) to describe appropriate, intended future device modifications. The Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research in consultation with the Center for Drug […]
Written by
  1. Life Sciences

FDA Pushes Back Enforcement Deadline for MoCRA Facility Registration and Product Listing Requirements – Duane Morris Life Sciences Law

Today, FDA announced updated guidance regarding its MoCRA rollout. FDA  does not intend to enforce the requirements related to cosmetic product facility registration and cosmetic product listing for an additional six months after the December 29, 2023, statutory deadline, or until July 1, 2024, to provide regulated industry additional time to comply with these requirements. To […]
Written by
  1. Life Sciences

House Oversight Committee Gives Pharmacy Benefit Managers Deadline to Correct Congressional Record of Allegedly Fraudulent Statements

On August 28, 2024, the U.S. House Committee on Oversight and Accountability issued letters to executives of three of the nation’s largest pharmacy benefit managers (PBMs), accusing them of providing false testimony before Congress. Each letter outlines the allegedly false statements and the evidence that the statements contradict. They also outline […]
Written by
  1. Life Sciences

FDA’s Second Warning Letter of the Year Deals with Potentially Misleading Efficacy Claims About Inhaler – Duane Morris Life Sciences Law

On August 15, 2023, the U.S. Food and Drug Administration (FDA) published a warning letter to AstraZeneca Pharmaceuticals LP, alleging that a professional sales brochure for its Breztri Aerosphere (budesonide, glycopyrrolate and formoterol fumarate) inhalation aerosol contained false or misleading claims regarding the drug’s efficacy. In view of the warning letter—only the second of […]
Written by
  1. Life Sciences

Bayh-Dole Act March-In Rights A part of White Home Plan to Decrease Drug Costs – Duane Morris Life Sciences Legislation

Following enactment of the Inflation Discount Act, which gives for Medicare drug worth negotiations, the White Home has introduced new actions to decrease drug prices, together with the discharge of a proposed framework for businesses to train march-in rights beneath the Bayh-Dole Act to advertise public accessibility to tax-payer-funded medication. If adopted, the […]
Written by
  1. Life Sciences

Federal Court Enjoins Enforcement of NIH’S Rate Change Notice Regarding Indirect Costs – Duane Morris Life Sciences Law

By Dan Walworth, Rolando Sanchez, Frederick Ball, Geoffrey Goodale and Sara Smith Since taking office, the Trump Administration has taken steps to reshape the United States’ federal funding infrastructure. One such action relates to the National Institutes of Health’s (“NIH”) rate change, imposing a 15% cap for indirect costs, for new grants and for existing […]
Written by
  1. Life Sciences

Take Care When Paying Volume-Based Compensation to Sales Agents to Avoid Anti-Kickback Statute Violations – Duane Morris Life Sciences Law

By  Frederick R. Ball, Coleen W. Hill and Victoria (Tori) Hawekotte Pharmaceutical companies sometimes compensate sales agents per volume sold. The Fifth and Seventh Circuits have indicated that a company may structure such arrangements without running afoul of the Anti-Kickback Statute (AKS). However, such arrangements carry risk of violating the AKS and should […]
Written by
  1. Life Sciences

Federal Circuit Court Affirms Delisting of Patents Claiming Device Components of Drug Product Without Active Ingredient

In Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC (No. 2024-1936), the Federal Circuit affirmed the District Court of New Jersey’s order to delist from the FDA Orange Book Teva’s five patents claiming just device components of a drug product without reciting any active ingredient. Read the full Alert […]
Written by
  1. Life Sciences

First Circuit Embraces More Restrictive View of False Claims Act Kickback Enforcement Provision – Duane Morris Life Sciences Law

By: Daniel R. Walworth, Christopher H. Casey, Frederick R. Ball, Erin M. Duffy and Joseph R. Welsh The United States Court of Appeals for the First Circuit’s opinion in United States v. Regeneron Pharmaceuticals, Inc. has sharpened the circuit split for demonstrating the effect of a kickback on healthcare decisions under the False Claims […]
Written by
  1. Life Sciences

FTC Voices Help for March-In Rights on Patents to Assist Management Drug Costs – Duane Morris Life Sciences Legislation

The Federal Commerce Fee (FTC) has introduced its help of the federal authorities’s use of “march-in rights” as a mechanism to regulate the worth of prescription drugs. The Nationwide Institute of Requirements and Know-how (NIST) late final yr issued its “Draft Interagency Steerage Framework for Contemplating the Train of March-In Rights” that might […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: Cybersecurity and Data Privacy Concerns for Wearables – Duane Morris Life Sciences Law

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.